New cocktail of drugs and radiation targets tough pancreatic tumors
NCT ID NCT05411094
First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 3 times
Summary
This early-phase trial is testing whether combining the targeted drug olaparib, the immunotherapy durvalumab, and radiation therapy is safe for people with locally advanced pancreatic cancer that cannot be surgically removed. The study enrolls 18 participants who have already received first-line chemotherapy. Researchers are looking for the best dose and checking for side effects, as well as tracking how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- olaparib (a PARP inhibitor) and durvalumab (an immunotherapy drug)
- What this could lead to
- If it works, this could point toward a new treatment option for people with locally advanced pancreatic cancer that cannot be removed by surgery.
- What could go wrong
- This is a very early phase 1 trial with only 18 participants, so results may not apply to everyone. The study is currently suspended, and combining these treatments may cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, 92612, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
University of Michigan - Brighton Center for Specialty Care
Brighton, Michigan, 48116, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin, 53718, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Decades-Old parasite drug help fight pancreatic cancer?
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Can a tailored web portal help pancreatic cancer patients exercise and eat better during chemotherapy?
- New drug AB801 aims to boost chemo and immunotherapy in tough cancers
- New drug cocktail targets tough pancreatic tumors
- New PET tracer could light up pancreatic tumors